

¹⁸
14. (New) A method according to claim 11, wherein said method avoids significant onset delay in effecting such treatment and avoids on-off phenomena in such treatment, said oral dosage formulation consisting of said immediate release layer and said sustained release layer, said immediate release layer providing rapid onset of anti-Parkinson activity and said sustained release layer providing sustained anti-Parkinson activity.

¹⁹
X 15. (New) A method for treating Parkinson's disease in a patient having need of such treatment comprising orally administering to said patient an oral dosage formulation in capsule form, said capsule containing uncoated core pellets consisting essentially of sugar spheres coated with levodopa, carbidopa, and povidone, said uncoated core pellets being formulated to provide immediate release and being in an amount to provide rapid onset of anti-Parkinson activity; and sustained release pellets consisting essentially of sugar spheres layered with a coating formed from a slurry of micronized levodopa and carbidopa in povidone, said sustained release pellets having an outer polymer coating, said sustained release pellets being formulated to provide sustained release and in an amount to provide sustained anti-Parkinson activity.

²⁰
+ 16. (New) A method according to claim ¹⁹15, wherein said polymer coating is formed from a polyethylene glycol and an ethylcellulose.

²¹
424/472 17. (New) A method for treating Parkinson's disease in a patient having need of such treatment comprising orally administering an at least one bi-layered tablet to said patient, said tablet having a sustained release core layer consisting essentially of carbidopa, levodopa, methocel, microcrystalline cellulose, silicon dioxide and magnesium stearate, and an immediate release outer layer over said sustained release core layer, said immediate release layer consisting essentially of carbidopa, levodopa, microcrystalline cellulose, croscarmellose sodium, silicon dioxide, and magnesium stearate.

²²
18. (New) A method according to claim ²¹17, wherein said immediate release outer layer contains 12.5 mg carbidopa, 50 mg of levodopa, 123.5 mg. of microcrystalline cellulose, 2.0 mg of silicon dioxide, 10 mg of magnesium stearate, the mg being mg/tablet.

In re Appln. of RUBIN, Alan.
Application No. 08/835,482.

^{2/3}
~~19.~~ (New) A method according to claim ²¹~~17~~, wherein said sustained released core layer contains 37.5 mg of carbidopa, 150 mg levodopa, 80 mg methocel, 53.5 mg. microcrystalline cellulose, 2.0 mg silicon dioxide, and 2.0 mg magnesium stearate, the mg being mg/tablet.

See Appendix for changes